analyses have been carried out on CHD treatment with Le-Mai particle. Therefore, we systematically screened data for Le-Mai particle aiming to provide the evidence for the efficacy and safety of Le-Mai particle in patients with angina pectoris.
subjects ANd Methods

Search strategy
In order to obtain as many randomized controlled trials (RCTs) of Le-Mai particle therapy in patients with angina pectoris as possible, we searched the following databases from inception through August 1, 2018: China National Knowledge Infrastructure database, Wanfang database, China Science and Technology Journals database (VIP), Chinese Biomedical Literature database, PubMed, Cochrane Library, and Medline. We also used Internet resources to gather information (http://www.clinicaltrials.gov.http://www.clinicaltrialresults. org). The following terms were used: "Le-Mai particle" or "Le-Mai" or "Le Mai" in combination with "Angina pectoris" or "Angor pectoris" or "Angina" or "Acute coronary syndrome" and "CHD" or "Coronary artery disease" or "Cardiovascular disease" or "Angiocardiopathy" or "Atherosclerosis." There was no restriction on language or the type of publication.
Study selection
The inclusion criteria for studies were as follows: (1) RCTs; (2) participants were diagnosed with angina pectoris according to the criteria determined by the International Society of Federation of Cardiology and the World Health Organization; (3) experimental groups were treated with Le-Mai particle, regardless of blinding; (4) the evaluation of clinical curative effect should have recognized observational indexes and exact values, such as angina pectoris improvement rate, electrocardiogram (ECG) improvement rate, and cardiac function grading; (5) the sample size ≥40 in each group. The exclusion criteria were as follows: (1) incompatible or repeated research; (2) unclear diagnosis of the selected population; (3) lack of control group or other Chinese medicine were used as the control group; (4) incorrect or incomplete data; (5) no objective laboratory examination but only the evaluation of traditional Chinese medicine (TCM) treatment; (6) animal or cell experiments.
Data extraction and quality assessment
Data concerning details of participants, interventions, and outcomes were extracted independently by two reviewers. For dichotomous data, the number of total events and positive events in each group was extracted. For continuous outcomes, mean value, standard deviation, and the sample size of each group were imputed. The data extraction table included the following items: (1) general information: title, authors, and year of publication; (2) trials characteristics: design of independent researches and methods of randomization; (3) patients: total number, the number of the experimental group and the control group, age, diagnostic criteria, and withdrawals/losses to follow-up; (4) interventions and outcomes. Main observation indexes in this research included clinical angina improvement as the primary endpoint and ECG improvement as the secondary endpoint. The methodological quality of the included studies was scored using a modified Jadad scale. [18] Trials scoring 1-3 points were considered as low quality, whereas trials scoring 4-7 points were defined as high quality.
Statistical analysis
Data were analyzed using RevMan version 5.2 (Cochrane Collaboration, London, UK). Dichotomous data were analyzed using odds ratios (OR) with 95% confidence intervals (95% CI), and continuous variables were analyzed using standardized mean differences with 95% CI. The Chi-square test and I 2 statistic were used to assess the heterogeneity between the results of trials. When P > 0.1 and I 2 <50%, a fixed-effect model was applied. Otherwise, the random-effect model was applied. All P values were two-tailed, and the threshold for statistical significance was set at 0.05. The improvement rate of clinical symptoms was the primary evaluation index of drug efficacy. The clinical symptom improvement was defined as the frequency of angina pectoris reduced by >1/2 in 1 week, under the condition of patients maintaining the same labor intensity as before. ECG was one of the most crucial objective laboratory examinations. Hence, it was also used to evaluate the effect of Le-Mai particle on the treatment of CHD. ECG improvement was defined as ST segment increasing at least 0.05 mV or reaching nearly normal level under exercise test. If the number of included trials was adequate, funnel plot in combination with the fail-safe number (Nfs 0.05) was chosen to assess the potential publication bias.
Results liteRAtuRe seARchiNg Results
After inputting search terms in all database and websites as mentioned above, 46 records were identified. Among the 46 articles, 34 with repetitive contents were deleted and 12 remaining records were downloaded for elaborative assessment. Four records were excluded due to not meeting the inclusion criteria. One record was excluded because it used other Chinese medicine in the control group. One record did not have objective laboratory examination. Finally, a total of six records were found to be well qualified. [13] [14] [15] [16] [17] 19] Basic characteristics and quality assessment of included studies Six RCTs, [13] [14] [15] [16] [17] 19] enrolling 557 patients with angina pectoris, were identified in the study. 279 patients in the experimental group were treated with Le-Mai particle and conventional Western medicine (CWM), and 278 patients in the control group were given CWM alone for treatment. The quality of the included studies was generally low. Jadad scores for all studies were no >3 points. The basic characteristics of the six included studies are shown in Table 1 .
Data analysis
As shown in Table 2 , treatment with Le-Mai particle exhibited a better therapeutic effectiveness in both angina symptom (OR = 3.85, 95% CI = 2.38-6.24, P < 0.00001) and ECG improvement (OR = 1.98, 95% CI = 1.38-2.85, P = 0.0002) in comparison with control therapy.
The adverse reaction was used to evaluate the safety of Le-Mai particle in patients with angina pectoris. All literature involved mentioned adverse reaction. When compared with CWM alone, no significant increase in the adverse reaction was observed in the Le-Mai treatment group. Further studies with larger sample sizes were needed to confirm the result.
Publication bias and sensitivity analysis
In this study, funnel plots and Nfs 0.05 were used to analyze the publication bias of the observed outcomes. The funnel plot was roughly symmetric, which meant that no conspicuous publication bias was found (data not shown). The Nfs 0.05 value of clinical angina effect was calculated as 58.3, which meant that 58.3 negative independent studies were required to reverse the conclusion. The Nfs 0.05 value of ECG improvement was counted as 23.5, which meant that 23.5 negative independent studies were needed to deny the efficacy of Le-Mai particle on ECG improvement. Both 58.3 and 23.5 were higher than 6 (six independent studies involved in our analysis). Thus, there was no significant publication bias in the pooled analysis.
discussioN
Our study showed that Le-Mai particle was effective in improving clinical angina symptoms and abnormal ECG. No significant increase in the adverse reaction was observed in the Le-Mai treatment group compared with the control group. To the best of our knowledge, this is the first pooled analysis providing comprehensive insights into the efficacy and safety of Le-Mai particle on angina pectoris. Our pooled analysis provided strong evidence that Le-Mai particle could be widely used in clinical for patients with angina pectoris.
Le-Mai particle, as one complicated prescription, is composed by S. miltiorrhiza Bunge (31.9%), L. chuanxiong Hort (15.9%), Radix Paeoniae Rubra (15.9%), C. tinctorius L (15.9%), C. rotundus (7.9%), Radix Aucklandiae (7.9%), and C. Pinnatifida Bunge (7.9%). [10] [11] [12] Modern pharmacological researches showed that S. miltiorrhiza Bunge was an excellent slow calcium-channel blocker which could prevent the damage of the membrane's structure and function under the condition of ischemia and hypoxia. [20] L. chuanxiong Hort mainly acts as a calcium antagonist; it can regulate the release of various vasoactive substances and improve the microcirculation. [21] Radix Paeoniae Rubra can expand the blood vessel and increase coronary blood flow. [22] C. tinctorius L is an oxygen-free radical scavenger, which can inhibit platelet aggregation and reduce blood viscosity. [23] C. rotundus and Radix Aucklandiae can reduce blood viscosity and relieve pain. [24, 25] Taken together, these studies suggest that Le-Mai particle works in many ways to cure angina pectoris such as dilating blood vessels and reducing blood viscosity, which is termed as invigorating the circulation of Qi and blood in TCM.
In China, Le-Mai particle has been used to treat angina pectoris for a long time. The government of Canada is ready to launch this TCM on the domestic market. However, so far, no pooled analysis has been performed on the beneficial effects of Le-Mai particle on angina pectoris. Thus, this study provides the first PRISMA-compliant pooled analysis to examine the efficacy and safety of Le-Mai particle. This pooled analysis supports the clinical efficacy of Le-Mai particle in the treatment of angina pectoris, which is consistent with most published RCT findings. Therefore, it is recommended to treat angina pectoris of CHD by using both CWM and Le-Mai particle. However, it is not clear whether the curative effect of Le-Mai single drug is better than that of CWM.
There are several potential limitations in this pooled analysis. First, this pooled analysis only included published RCTs and some negative results may not be published, which may lead to selection bias. Second, the sample size was small, and the duration of intervention was short, which might not be able to provide precise results for the efficacy of Le-Mai particle. Therefore, studies with relatively larger sample sizes and longer duration are needed to accurately verify the efficacy and safety of Le-Mai particle in treating angina pectoris.
coNclusioN
Our study provides preliminary evidence that supports the use of Le-Mai particle as a potentially optimistic and reliable intervention for angina pectoris. Nevertheless, despite our rigorous methodology, the inherent limitations of included studies prevent us from reaching definitive conclusions. Future strictly designed, multi-center, large-scale, and long-term clinical trials are awaited to improve and update the findings of effectiveness and safety of Le-Mai particle for angina pectoris.
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